Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluocinolone acetonide + neomycin + polymyxin B
- Development stage
- Unknown
- Lead developer
- DÁVI
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides
- Administration
- Otic
01
Overview
Otosynalar (also known as Oto-Synalar N) is a combination ear drop solution containing fluocinolone acetonide (a synthetic fluorinated corticosteroid), neomycin (an aminoglycoside antibiotic), and polymyxin B (a polypeptide antibiotic). It is indicated for the treatment of external otitis and other inflammatory conditions of the ear that are responsive to steroids, particularly when there is suspicion or risk of bacterial infection. Fluocinolone acetonide acts as an anti-inflammatory agent by suppressing immune responses and reducing inflammation. Neomycin inhibits bacterial protein synthesis by binding to ribosomal RNA, while polymyxin B disrupts bacterial cell membrane integrity. This combination provides both anti-inflammatory and antibacterial effects for localized ear infections[2][4].
- Brand names
- OtosynalarOto-Synalar N
- Other names
- OtosynalarOto-Synalar N
02
Targets
GR (Glucocorticoid receptor)LPS (Lipopolysaccharide)30S A-site (Bacterial ribosomal 30S A-site)
Beyond the preview
Go deeper on fluocinolone acetonide + neomycin + polymyxin B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluocinolone acetonide + neomycin + polymyxin B.